Apellis Pharmaceuticals Set to Shine at Key Conferences
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) is ready to take center stage at two significant upcoming investor conferences in December. This participation reflects the company's commitment to transparency and engagement with the investment community as it continues to pave the way in innovative therapeutic solutions.
Details of the Conferences
During the month of December, Apellis Pharmaceuticals will engage with investors through the following scheduled presentations:
- Evercore ISI HealthCONx Conference: A fireside chat is set for Wednesday, December 4, at 9:10 a.m. ET.
- Citi Global Healthcare Conference: Another fireside chat is scheduled for Thursday, December 5, at 1:00 p.m. ET.
Accessing Live Webcasts
For investors and interested parties looking to tune in, the live webcasts of these conferences will be accessible through the company's dedicated 'Events and Presentations' page. This section can be found under the 'Investors and Media' tab on the official Apellis Pharmaceuticals website. After the events, there will also be a replay of the webcasts available for approximately 90 days, ensuring that those unable to join live can still catch up on important developments.
A Look at Apellis Pharmaceuticals
Apellis Pharmaceuticals is a pivotal player in the biopharmaceutical realm, with a focus on addressing complex diseases through groundbreaking therapies. The company stands out for its commitment to incorporating both robust scientific research and compassionate care in its approach. It has introduced a new class of complement medicine, making significant strides and becoming a leader in treating diseases that have long been challenging for patients.
Innovations in Therapy
The innovations from Apellis Pharmaceuticals have brought forth two FDA-approved therapies targeting C3, marking a landmark achievement in the medical field. One of these therapies is particularly notable as it is the first-ever treatment approved for geographic atrophy, recognized as a leading cause of blindness globally. This breakthrough highlights the company’s potential in revealing the therapeutic capabilities of targeting C3 across various conditions, including serious retinal diseases, rare disorders, and neurological challenges.
Continuous Commitment to the Community
Apellis Pharmaceuticals is steadily working towards enhancing the quality of life for patients facing daunting health challenges. The company’s vision is not just about treatments, but about the overall wellbeing of those it serves. By developing effective therapies, the company aims to foster a healthcare landscape where patients have better options and outcomes.
Staying Connected
For more updates and insights into Apellis Pharmaceuticals’ latest initiatives and achievements, the company encourages stakeholders to visit its official website as well as follow its social media channels on Twitter and LinkedIn. This online engagement is crucial for keeping the community informed about their continued progress and innovations.
Frequently Asked Questions
What will Apellis Pharmaceuticals discuss at the December conferences?
Apellis Pharmaceuticals will highlight its recent advancements in biopharmaceuticals, particularly its innovative therapies and strategic initiatives.
How can I watch the conferences?
The live webcasts of the conferences will be available on the company's 'Events and Presentations' page in the 'Investors and Media' section of the Apellis Pharmaceuticals website.
What new therapies has Apellis developed?
Apellis has developed therapies that target C3, including an approved treatment for geographic atrophy, a significant cause of blindness worldwide.
How does Apellis engage with its community?
Apellis engages with its community through social media, its website, and by participating in industry events and conferences.
Who can I contact for more investor-related information?
For investor inquiries, you can contact Meredith Kaya via the provided email address.
